Intech Investment Management LLC Invests $240,000 in Sana Biotechnology, Inc. (NASDAQ:SANA)

Intech Investment Management LLC acquired a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 57,698 shares of the company’s stock, valued at approximately $240,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Integral Health Asset Management LLC boosted its stake in Sana Biotechnology by 22.4% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after purchasing an additional 220,000 shares during the period. Algert Global LLC acquired a new position in shares of Sana Biotechnology during the second quarter worth approximately $73,000. XTX Topco Ltd bought a new position in Sana Biotechnology in the 2nd quarter worth approximately $100,000. Bank of New York Mellon Corp increased its position in Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock valued at $2,357,000 after acquiring an additional 90,423 shares during the period. Finally, Dark Forest Capital Management LP raised its stake in Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after acquiring an additional 14,430 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Wall Street Analyst Weigh In

SANA has been the topic of a number of recent analyst reports. Citigroup lifted their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th. Finally, JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Insider Buying and Selling

In related news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 31.10% of the company’s stock.

Sana Biotechnology Trading Down 12.1 %

NASDAQ:SANA opened at $2.30 on Friday. The company has a 50-day moving average of $3.43 and a 200-day moving average of $4.98. The firm has a market cap of $512.40 million, a price-to-earnings ratio of -1.64 and a beta of 1.33. Sana Biotechnology, Inc. has a twelve month low of $2.29 and a twelve month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.